157 related articles for article (PubMed ID: 31882700)
1. Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients.
Kitazawa H; Takeda Y; Naka G; Sugiyama H
Sci Rep; 2019 Dec; 9(1):19872. PubMed ID: 31882700
[TBL] [Abstract][Full Text] [Related]
2. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.
Ikeda S; Yoshioka H; Ikeo S; Morita M; Sone N; Niwa T; Nishiyama A; Yokoyama T; Sekine A; Ogura T; Ishida T
BMC Cancer; 2017 Nov; 17(1):797. PubMed ID: 29183294
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
4. Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer.
Sim SH; Kim YJ; Kim SH; Keam B; Kim TM; Lee SH; Kim DW; Heo DS; Lee JS
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1073-81. PubMed ID: 25410789
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
6. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial.
Dancey J; Shepherd FA; Gralla RJ; Kim YS
Lung Cancer; 2004 Feb; 43(2):183-94. PubMed ID: 14739039
[TBL] [Abstract][Full Text] [Related]
7. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy.
Thongprasert S; Sanguanmitra P; Juthapan W; Clinch J
Lung Cancer; 1999 Apr; 24(1):17-24. PubMed ID: 10403690
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of
Masuda T; Wakabayashi YU; Nakashima T; Nishimura Y; Shimoji K; Yamaguchi K; Sakamoto S; Horimasu Y; Miyamoto S; Senoo T; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Anticancer Res; 2021 May; 41(5):2661-2667. PubMed ID: 33952497
[TBL] [Abstract][Full Text] [Related]
9. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).
Roszkowski K; Pluzanska A; Krzakowski M; Smith AP; Saigi E; Aasebo U; Parisi A; Pham Tran N; Olivares R; Berille J
Lung Cancer; 2000 Mar; 27(3):145-57. PubMed ID: 10699688
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy versus best supportive care for extensive small cell lung cancer.
Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
Cochrane Database Syst Rev; 2013 Nov; (11):CD001990. PubMed ID: 24282143
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study.
Seto Y; Kaneko Y; Mouri T; Fujii H; Tanaka S; Shiotsu S; Hiranuma O; Morimoto Y; Iwasaku M; Yamada T; Uchino J; Takayama K
Transl Lung Cancer Res; 2021 Jan; 10(1):193-201. PubMed ID: 33569304
[TBL] [Abstract][Full Text] [Related]
13. What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.
Lester JF; Agulnik J; Akerborg O; Chouaid C; De Geer A; Finnern HW; Herder GJ; Lungershausen J; Mitchell PL; Vansteenkiste J; Ziske C; Goker E
Lung Cancer; 2013 Oct; 82(1):128-35. PubMed ID: 23910909
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
Brueckl WM; Achenbach HJ; Ficker JH; Schuette W
BMC Cancer; 2018 Mar; 18(1):333. PubMed ID: 29587656
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more.
Tamiya A; Naito T; Ono A; Ayabe E; Tsuya A; Nakamura Y; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
Lung Cancer; 2011 Feb; 71(2):173-7. PubMed ID: 20570388
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
17. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
Goldman JW; Shi P; Reck M; Paz-Ares L; Koustenis A; Hurt KC
Clin Lung Cancer; 2016 Jan; 17(1):80-4. PubMed ID: 26432508
[TBL] [Abstract][Full Text] [Related]
18. Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy?
Numico G; Russi E; Merlano M
Lung Cancer; 2001 Jun; 32(3):213-26. PubMed ID: 11390003
[TBL] [Abstract][Full Text] [Related]
19. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
[TBL] [Abstract][Full Text] [Related]
20. Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan.
Murakawa Y; Sakayori M; Otsuka K
BMC Palliat Care; 2019 Jun; 18(1):45. PubMed ID: 31159782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
